Improvement of survival for non-small cell lung cancer over time

Figures & data

Table 1 Demographic and clinicopathological characteristics of patients with NSCLC

Characteristics	Total number N=405,580, n (%)	Year of diagnosis				P-value
		1988–1992 n=50,035, n (%)	1993–1997 n=64,179, n (%)	1998–2002 n=115,163, n (%)	2002–2008 n=176,203, n (%)
Ages (median =68)						<0.001
<50	28,351 (6.99)	7.64	7.28	7.13	6.61
50–59	69,609 (17.16)	17.38	16.49	17.3	17.26
60–69	123,926 (30.56)	35.46	31.94	29.15	29.58
70–79	129,533 (31.94)	30.26	33.02	33.09	31.26
>80	54,161 (13.35)	9.26	11.27	13.33	15.3
Sex						<0.001
Male	231,101 (56.98)	62.82	58.84	56.88	54.71
Female	174,479 (43.02)	37.18	41.16	43.12	45.29
Race						<0.001
White	331,360 (81.70)	82.82	80.6	82.15	81.49
Black	47,417 (11.69)	11.61	11.85	11.53	11.76
Other	26,152 (6.45)	5.51	7.42	6.16	6.55
Unknown	651 (0.16)	0.06	0.13	0.15	0.2
Summary stage						<0.001
Localized	71,822 (17.71)	17.97	18.09	17.33	17.74
Regional	101,239 (24.96)	27.29	27.73	24.35	23.69
Distant	209,506 (51.66)	45.07	46.84	52.01	55.05
Unstaged	23,013 (5.67)	9.67	7.33	6.31	3.52
Surgery						<0.001
No	295,978 (72.98)	72.03	72.34	73.18	73.34
Yes	107,268 (26.45)	27.82	27.42	26.1	25.93
Unknown	2,334 (0.58)	0.15	0.23	0.73	0.72
LN status						<0.001
Negative	67,040 (16.53)	15.68	15.26	16.43	17.3
Positive	50,921 (12.56)	13.97	13.14	12.49	11.98
No nodes examined	279,381 (68.88)	68.32	70.43	68.76	68.56
Unknown	8,238 (2.03)	2.03	1.17	2.32	2.15
Grade						<0.001
I	17,667 (4.36)	4.01	4.14	4.09	4.7
II	64,574 (15.92)	15.00	15.49	15.67	16.51
III	129,877 (32.02)	35.60	36.87	32.24	29.09
IV	18,962 (34.68)	8.66	7.28	4.49	2.72
Unknown	174,500 (43.02)	36.73	36.21	43.51	46.98
Pathological type						<0.001
Squamous cell	102,511 (25.28)	31.15	27.12	24.75	23.28
Adenocarcinoma	167,166 (41.22)	40.27	42.57	41.11	41.06
Others or NSCLC NOS	135,903 (33.50)	28.58	30.31	34.14	35.65

Note: Chi-square analysis was used to compare proportions for all categorical data.

Abbreviations: NOS, not otherwise specified; NSCLC, non-small cell lung cancer; LN, lymph node.

Figure 1 Trends of demographic and clinicopathological characteristics for NSCLC from 1988 to 2008. Sample means (A: age of diagnosis) and proportions (B: summary stage; C: lymph node metastasis; D: histological grade; E: sex; and F: pathological type) of NSCLC cases are shown by year of diagnosis. One-way ANOVA analysis (A) and Cochran–Armitage trend test (B–F) were used, all P-values <0.001.

Figure 2 Kaplan–Meier survival analysis for overall (A) and specific stages of patients: (B) Localized, (C) Regional, and (D) Distant, with NSCLC between 1988 and 2008 grouped by periods of diagnosis. All P-values <0.001.

Figure 3 Trend of surgery rate (A) and Kaplan–Meier survival analysis for surgical (B) and non-surgical (C) groups. Cochran–Armitage trend test was used to evaluate trend (A); all P-values <0.001.

Figure 4 Trend of distribution of surgical approaches for NSCLC cases (A) and Kaplan–Meier survival analysis for specific surgical approaches (B) lobectomy, (C) pneumonectomy, and (D) partial/wedge/segmental resection. Cochran–Armitage trend test was used to evaluate trend (A); all P-values <0.001.